Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.

Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, London, UK.
The Lancet Neurology (Impact Factor: 21.82). 12/2009; 8(12):1140-9. DOI: 10.1016/S1474-4422(09)70287-X
Source: PubMed

ABSTRACT Dopamine is an essential neurotransmitter for many brain functions, and its dysfunction has been implicated in both neurological and psychiatric disorders. Parkinson's disease is an archetypal disorder of dopamine dysfunction characterised by motor, cognitive, behavioural, and autonomic symptoms. While effective for motor symptoms, dopamine replacement therapy is associated not only with motor side-effects, such as levodopa-induced dyskinesia, but also behavioural side-effects such as impulse control disorders (eg, pathological gambling and shopping, binge eating, and hypersexuality), punding (ie, abnormal repetitive non-goal oriented behaviours), and compulsive medication use. We review clinical features, overlapping molecular mechanisms, and a specific cognitive mechanism of habit learning that might underlie these behaviours. We integrate these mechanisms with the emerging view of the basal ganglia as a distributive system involved in the selection and facilitation of movements, acts, and emotions.

Download full-text


Available from: Pierre-Olivier Fernagut, Jun 29, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Beyond dopamine (DA) loss, Parkinson's disease is associated with many other monoamine alterations. While some monoaminergic systems benefit from l-3,4-dihydroxyphenylalanine (l-Dopa) treatment, others seem to be further altered, contributing to dyskinesia and nonmotor symptoms. Surprisingly, the different contributions of parkinsonism and l-Dopa treatment on monoaminergic changes remain largely unknown. Here, both the consequences of vehicle or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure and the subsequent effects of acute or chronic l-Dopa treatment were evaluated in macaques. Monoamine levels were measured in the putamen, the motor and prefrontal cortices, the hippocampus, and the amygdala using postmortem high-pressure liquid chromatography. In normal monkeys, l-Dopa treatment increased DA in the prefrontal cortex and hippocampus, but decreased serotonin levels in motor domains. Chronic l-Dopa treatment elevated monoamine levels in the prefrontal cortex, hippocampus, and amygdala in both normal and MPTP-treated monkeys. A substantial increase in DA levels in these regions, paralleled by a decrease in serotonin concentrations were related with dyskinesia severity, demonstrating that major changes in monoamine release also occur in nonmotor regions. Such monoaminergic dysregulation in limbic domains may also directly contribute to the expression of motor complications, such as dyskinesia, by impairing integrative processes upstream from motor execution.
    Cerebral Cortex 04/2014; DOI:10.1093/cercor/bhu076 · 8.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-motor symptoms contribute significantly to Parkinson's disease (PD) related disability. Impulse control disorders (ICDs) have been recently added to the behavioural spectrum of PD-related non-motor symptoms. Such behaviours are characterized by an inappropriate drive to conduct repetitive behaviours that are usually socially inadequate or result in harmful consequences. Parkinson disease impulse control disorders (PD-ICDs) have raised significant interest in the scientific and medical community, not only because of their incapacitating nature, but also because they may represent a valid model of ICDs beyond PD and a means to study the physiology of drive, impulse control and compulsive actions in the normal brain. In this review, we discuss some unresolved issues regarding PD-ICDs, including the association with psychiatric co-morbidities such as obsessive-compulsive disorder and with dopamine related side effects, such as hallucinations and dyskinesias; the relationship with executive cognitive dysfunction; and the neural underpinnings of ICDs in PD. We also discuss the contribution of neuroscience studies based on animal-models towards a mechanistic explanation of the development of PD-ICDs, specifically regarding corticostriatal control of goal directed and habitual actions.
    Behavioural neurology 12/2012; 27(4). DOI:10.3233/BEN-129019 · 1.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms. There are several models both of basal ganglia (BG) function and their dysfunction in PD. Degeneration of the nigrostriatal dopaminergic pathway is the key pathological feature of PD, leading to classical motor symptoms, such as bradykinesia and rigidity. A dysfunction of structures other than BG, including cerebellum and brainstem, may be involved in the generation of tremor and axial symptoms, while the degeneration of non-dopaminergic neurotransmitter systems is a likely contributing factor of non-motor symptoms. BG models provide hypotheses testable by electrophysiological research in humans. In PD patients with implanted deep brain stimulators, activity from BG nuclei, i.e. the subthalamic nucleus the internal pallidal segment, and from the peduncolopontine nucleus may be directly recorded using depth electrodes. Non-invasive electrophysiological techniques allow the investigation of dysfunctional BG through interconnections with motor cortical areas, brainstem and spinal structures. Electrophysiological studies have revealed functional abnormalities at every level of the central nervous systems, including BG nuclei, motor cortex, cerebellum, brainstem and spinal cord. Despite the progress in electrophysiological characterization of PD, with particular advances in understanding the role of pathological BG oscillatory activity in generating bradykinesia, there is still a large gap in understanding the pathophysiological relevance of other electrophysiological findings in PD. Better insight into the relationship between electrophysiological abnormalities and motor and non-motor symptoms in PD is likely to have important clinical implications.
    12/2012; 2(4):189–193. DOI:10.1016/j.baga.2012.05.007